Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the transaction, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Orbimed Advisors Llc also recently made the following trade(s):
- On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total transaction of $2,664,412.86.
- On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.61, for a total transaction of $2,165,637.06.
- On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
- On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total value of $2,341,097.96.
- On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total value of $10,287,918.04.
- On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32.
- On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14.
Sionna Therapeutics Price Performance
Shares of Sionna Therapeutics stock traded up $1.72 during trading on Monday, hitting $45.95. The stock had a trading volume of 670,726 shares, compared to its average volume of 344,329. The business has a fifty day moving average of $38.55 and a two-hundred day moving average of $39.36. Sionna Therapeutics, Inc. has a fifty-two week low of $11.77 and a fifty-two week high of $48.45. The firm has a market cap of $2.07 billion, a P/E ratio of -23.56 and a beta of 1.35.
Institutional Investors Weigh In On Sionna Therapeutics
A number of large investors have recently made changes to their positions in SION. Goldman Sachs Group Inc. acquired a new stake in shares of Sionna Therapeutics during the first quarter valued at approximately $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics during the first quarter valued at approximately $837,000. Geode Capital Management LLC raised its holdings in shares of Sionna Therapeutics by 113.4% during the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after acquiring an additional 153,712 shares during the period. Rhumbline Advisers acquired a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $307,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $118,000.
Analysts Set New Price Targets
SION has been the subject of several recent research reports. Wedbush assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Citizens Jmp assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $53.00.
Read Our Latest Analysis on Sionna Therapeutics
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
